Pfizer’s Growth Prospects Amidst Challenges: A Hold Rating Analysis

In a report released today, Steve Scala from TD Cowen maintained a Hold rating on Pfizer, with a price target of $30.00.

Steve Scala has given his Hold rating due to a combination of factors that reflect both challenges and potential growth opportunities for Pfizer. One of the primary considerations is the anticipated period of stable sales over the next few years, influenced by the loss of exclusivity (LOE) on key products. This LOE is expected to exert financial pressure, with significant impacts projected in 2026, 2027, and 2028. However, Pfizer is optimistic about a subsequent phase of growth acceleration from 2028 to 2030, driven by new product opportunities.
Additionally, Pfizer’s management has expressed confidence in the company’s international operations, which have shown a notable turnaround and are now contributing positively to growth. Despite these positive signs, the analyst remains cautious, as the full potential for growth recovery is contingent on upcoming data readouts from key studies. This cautious optimism, balanced by the current challenges, underpins the Hold rating, suggesting that while there are promising prospects, uncertainties remain that could affect the stock’s performance.